Compare Gilead Sciences, Inc. (GILD) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Monolithic Power Systems Inc — how do they compare? Gilead Sciences, Inc. trades at $135.67 (market cap $163.51B), while Monolithic Power Systems Inc trades at $1,301.42 (market cap $66.46B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× Monolithic Power Systems Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MPWR | |
|---|---|---|
Market Cap | $163.51B | $66.46B |
Sector | Health | Utilities |
52-Week High | $155.80 | $1.69K |
52-Week Low | $108.22 | $711.24 |
Enterprise Value | $178.05B | $65.11B |
Dividend Yield | 2.49% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Monolithic Power Systems (MPWR) trades at $1,297.85, down 5.71% on the day, amid a neutral technical backdrop. The stock exhibits strong fundamentals with consistent earnings beats, a 22.98% net income margin, and robust cash flow. Analyst sentiment is overwhelmingly bullish with an 88% buy rating and a consensus price target of $1,810, suggesting significant upside. Recent news highlights the company's positioning in the AI infrastructure and power semiconductor boom.
The outlook for MPWR is positive, driven by demand in data centers, EVs, and AI, though high valuation multiples pose a risk. Investment opportunity lies in its growth trajectory and market leadership, balanced by competitive pressures and ongoing legal scrutiny. The stock's performance hinges on execution in expanding markets and maintaining profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
